Collaboration and License Agreement (Details) $ / shares in Units, $ in Thousands	1 Months Ended		3 Months Ended
	Mar. 31, 2023 USD ($) product item $ / shares shares	Aug. 31, 2021 shares	Mar. 31, 2023 USD ($) $ / shares	Mar. 31, 2022 USD ($)	Apr. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaboration and License Agreement
Issuance of common stock in connection with the Moderna Agreement, shares | shares		1,795,524
Proceeds from issuance of common stock in connection with the Moderna Agreement			$ 36,000	$ 0
Contract with customer liability, current	$ 5,681		5,681			$ 0
Contract with customer liability, noncurrent	55,085		55,085			$ 0
Collaboration and License Agreement | ModernaTX, Inc
Collaboration and License Agreement
Upfront payments	40,000		40,000		$ 40,000
Prepaid research services funding	7,500		7,500		$ 7,500
Milestone payments receivable	$ 1,800,000		$ 1,800,000
Issuance of common stock in connection with the Moderna Agreement, shares | shares	5,859,375
Shares issue price (in dollars per share) | $ / shares	$ 6.14		$ 6.14
Proceeds from issuance of common stock in connection with the Moderna Agreement	$ 36,000
Percent of shares to be issued	3.06%
Equity financing	$ 25,000		$ 25,000
Number of performance obligations | item	1
Premium paid on common stock	$ 13,300		13,300
Variable consideration	0		0
Revenue recognized			0
Contract with customer liability, current	5,700		5,700
Contract with customer liability, noncurrent	$ 55,100		$ 55,100
Collaboration and License Agreement | ModernaTX, Inc | Minimum
Collaboration and License Agreement
Number of products to be commercialized | product	1
Royalty payment term	10 years